- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- KPI-012, KPI-012 Vehicle
- Drug
- Lead sponsor
- Combangio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Irvine, California • La Jolla, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 7,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
- Interventions
- CMV hyperimmune globulin, Placebo
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 399 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
- Conditions
- Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Methazolamide 25 MG, Methazolamide 50 MG
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- MammaPrint, BluePrint, and Full-Genome Testing
- Diagnostic Test
- Lead sponsor
- Agendia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2037
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 107 more
- Conditions
- Type 1 Diabetes, Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Viral N. Shah
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • West Des Moines, Iowa • Detroit, Michigan + 1 more
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 632 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
- Conditions
- Fractures
- Interventions
- rhBMP-2/CPM
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Denver, Colorado + 6 more
- Conditions
- Advanced Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
- Drug · Biological
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 185
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
- Conditions
- Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma
- Interventions
- Laboratory Biomarker Analysis, Retroperitoneal Lymph Node Dissection
- Other · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 14
- States / cities
- Loma Linda, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Iron Deficiency, Iron Deficiency Anemia
- Interventions
- Vitamin E, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 9 Months to 2 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Primary Biliary Cholangitis
- Interventions
- seladelpar 5-10 mg, seladelpar 10 mg, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
- Conditions
- Survivors of Childhood Cancer, Bladder Dysfunction
- Interventions
- Non-invasive Urodynamic Test (niUDS), Urinary proteomic screen, Dysfunctional Voiding Symptom Score Survey (DVSS)
- Diagnostic Test · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 5 Years to 13 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Renal Transplant Patients
- Interventions
- Envarsus XR
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type I
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 6
- States / cities
- Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Pregnancy Related, COVID, Intestinal Atresia, Limb Anomaly
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Acute Pancreatitis
- Interventions
- RABI-767
- Drug
- Lead sponsor
- Panafina, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, docetaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 160
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
- Conditions
- Myelofibrosis, Indolent Systemic Mastocytosis
- Interventions
- TL-895, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Rochester, Minnesota • Canton, Ohio + 3 more
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- avacincaptad pegol
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 53
- States / cities
- Campbell, California • Fresno, California • Fullerton, California + 49 more
- Conditions
- Aneurysm
- Interventions
- Not listed
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 17
- States / cities
- Santa Barbara, California • Englewood, Colorado • Gainesville, Florida + 14 more
- Conditions
- Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia, Carbamoyl-Phosphate Synthase I Deficiency Disease, Ornithine Carbamoyltransferase Deficiency
- Interventions
- Carbaglu, Placebo
- Drug
- Lead sponsor
- Mendel Tuchman
- Other
- Eligibility
- 1 Week to 99 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more
- Conditions
- Radiation Necrosis
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Autism Spectrum Disorder, Neurodevelopmental Disorders
- Interventions
- Not listed
- Lead sponsor
- Coalition for Aligning Science
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 7 more